Medical devices
Cognito reports Alzheimer’s trial results and plans FDA approval bid
In Cognito’s 663-person trial, sensory stimulation slowed decline on three measures in mild Alzheimer’s, but the overall study missed its primary endpoint.
Cognito Therapeutics announced results from its 12-month HOPE trial of Spectris, a device that uses 40Hz light and sound stimulation. The trial included 663 people with mild or moderate Alzheimer’s disease. The company said it plans to work with the FDA toward authorization for patients with mild Alzheimer’s.
The 395-person mild Alzheimer’s group showed statistically significant benefits on three measures, with slowed decline of 56% on ADCS-ADL, 53% on ADCS-iADL and 47% on CDR-SB, the company said. Among 169 mild patients who used the device at least 70% of the intended time, the reported slowed decline was 82%, 82% and 64% on those measures. The 268-person moderate group did not show clinical benefit, and the overall study did not meet its primary endpoint.


